Stockreport

TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients [Yahoo! Finance]

TRACON PHARMS INC  (TCON) 
Last tracon pharms inc earnings: 2/27 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: traconpharma.com
PDF Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment [Read more]